Erasmus School of Health Policy & Management
PhD candidate | Health Technology Assessment (HTA)
- xander@eshpm.eur.nl
More information
Work
- N. S.H. Xander, B. Leeneman, A. M.C. Dingemans, W. E. Fiets, W. K. de Jong, N. E.M. Uyl, A. N.M. Wymenga, A. K.L. Reyners & C. A. Uyl-de Groot (2024) - Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not? - European Journal of Cancer, 209 - doi: 10.1016/j.ejca.2024.114262 - [link]
- Brenda Leeneman, Nicolas S.H. Xander, W. Edward Fiets, Wouter K. de Jong, Nathalie E.M. Uyl, A. N.Machteld Wymenga, An K.L. Reyners & Carin A. Uyl-de Groot (2024) - Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness - European Journal of Cancer, 202 - doi: 10.1016/j.ejca.2024.114002 - [link]
- Nicolas S.H. Xander, W. Edward Fiets & Carin A. Uyl-de Groot (2023) - Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands - Frontiers in Oncology, 13 - doi: 10.3389/fonc.2023.1205700 - [link]
